Brief: Catalyst Biosciences Received Compliance Letter From Nasdaq Notifying Co It Has Regained Compliance With Minimum Bid Price Requirement
09/06/2022 11:11
June 9 (Reuters) - Catalyst Biosciences Inc CBIO.O :
* CATALYST BIOSCIENCES- ON JUNE 7 CO RECEIVED COMPLIANCE
LETTER
FROM NASDAQ NOTIFYING CO IT HAS REGAINED COMPLIANCE WITH MINIMUM
BID PRICE REQUIREMENT
Source text for Eikon: [https://bit.ly/3H7j5KQ]
Further company coverage: CBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes